Online inquiry

IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6657MR)

This product GTTS-WQ6657MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ITGAV gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001144999.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3685
UniProt ID P06756
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ6657MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11906MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ15841MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ10057MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ6002MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CNTO 095
GTTS-WQ8058MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ4472MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ2033MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ8628MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW